Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
X4 Pharmaceuticals, Inc amended credit facility of aggregate maximum borrowings of up to $115.0 million with Hercules Capital, Inc., as agent and lender, and Hercules Capital Funding IV LLC and Hercules Capital Funding Trust 2022-1, as lenders at greater of (i) 10.15% or (ii) 3.15% plus the Wall Street Journal prime rate maturing October 1, 2026; provided, however , such maturity date will be extended to July 1, 2027 if the Amortization Date is extended.
- Instrument
- credit facility
- Principal
- aggregate maximum borrowings of up to $115.0 million
- Counterparty
- Hercules Capital, Inc., as agent and lender, and Hercules Capital Funding IV LLC and Hercules Capital Funding Trust 2022-1, as lenders
- Rate
- greater of (i) 10.15% or (ii) 3.15% plus the Wall Street Journal prime rate
- Maturity
- October 1, 2026; provided, however , such maturity date will be extended to July 1, 2027 if the Amortization Date is extended
- Event
- amendment
Exact text from the filing
the Amendment upsizes the Company’s existing facilities and provides for a term loan facility of up to $115.0 million, including: (i) the $32.5 million Conversion Balance, which was deemed borrowed upon entering into the Amendment, (ii) a $22.5 million tranche, which the Company drew on the Closing Date of the Amendment
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
X4 Pharmaceuticals, Inc amended Amendment to Second Amended and Restated Loan and Security Agreement with Hercules Capital, Inc., as agent and lender, and Hercules Capital Funding IV LLC and Hercules Capital Funding Trust 2022-1, as lenders valued at aggregate maximum borrowings of up to $115.0 million (effective 2023-08-02).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Hercules Capital, Inc., as agent and lender, and Hercules Capital Funding IV LLC and Hercules Capital Funding Trust 2022-1, as lenders
- Value
- aggregate maximum borrowings of up to $115.0 million
- Effective
- 2023-08-02
Exact text from the filing
On August 2, 2023 (the “Closing Date”), X4 Pharmaceuticals, Inc. (the “Company”) and its subsidiary X4 Therapeutics, Inc. (together with the Company, the “Borrowers”) entered into an amendment (the “Amendment”) to the Existing Loan Agreement (as defined below) with Hercules Capital, Inc., as agent and lender, and Hercules Capital Funding IV LLC and Hercules Capital Funding Trust 2022-1, as lenders (collectively, “Hercules”), which provides for aggregate maximum borrowings of up to $115.0 million
View on SEC.gov